NLX-101 Improves Auditory Processing in Fragile X Mice
Author Information
Author(s): Tao Xin, Croom Katilynne, Newman-Tancredi Adrian, Varney Mark, Razak Khaleel A.
Primary Institution: University of California, Riverside
Hypothesis
NLX-101 will normalize EEG phenotypes in developing Fmr1 KO mice.
Conclusion
NLX-101 could be a promising treatment to improve auditory temporal processing in Fragile X Syndrome.
Supporting Evidence
- NLX-101 significantly reduced gamma band single trial power in Fmr1 KO mice at P30.
- Inter-trial phase clustering was significantly increased in both age groups with NLX-101.
- Saline-treated Fmr1 KO mice showed increased N1 amplitudes compared to wildtype mice.
Takeaway
Researchers gave a drug called NLX-101 to mice with Fragile X Syndrome to see if it would help them hear better. It worked for some things, making it easier for the mice to process sounds.
Methodology
The study used EEG recordings from male and female wildtype and Fmr1 KO mice to assess auditory processing after administering NLX-101 or saline.
Potential Biases
Potential bias in interpreting results due to the small sample size and specific strain of mice used.
Limitations
The study only tested acute administration of NLX-101 and did not explore long-term effects.
Participant Demographics
The study involved male and female Fmr1 KO and wildtype mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website